Monte Rosa Therapeutics IncNASDAQ:GLUE
- LAST PRICE3.8600
- TODAY'S CHANGE (%)0.2700 (7.5209%)
- Bid / Lots3.8400/ 5
- Ask / Lots3.8700/ 2
- Open / Previous Close3.5900 / 3.5900
- Day Range
- 52 Week Range
- Volume112,219
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GLUE |
|---|---|---|
| 09:32 ET | 4742 | 3.7099 |
| 09:34 ET | 960 | 3.6888 |
| 09:36 ET | 500 | 3.62 |
| 09:38 ET | 3312 | 3.68 |
| 09:39 ET | 500 | 3.66 |
| 09:41 ET | 175 | 3.61 |
| 09:43 ET | 100 | 3.65 |
| 09:45 ET | 100 | 3.64 |
| 09:50 ET | 2000 | 3.6519 |
| 09:54 ET | 629 | 3.6 |
| 09:56 ET | 700 | 3.61 |
| 09:57 ET | 200 | 3.61 |
| 09:59 ET | 7037 | 3.646 |
| 10:01 ET | 234 | 3.61 |
| 10:03 ET | 300 | 3.605 |
| 10:06 ET | 200 | 3.6 |
| 10:08 ET | 200 | 3.63 |
| 10:10 ET | 1018 | 3.635 |
| 10:14 ET | 1480 | 3.635 |
| 10:15 ET | 100 | 3.635 |
| 10:17 ET | 650 | 3.72 |
| 10:19 ET | 200 | 3.73 |
| 10:24 ET | 100 | 3.75 |
| 10:26 ET | 3145 | 3.74 |
| 10:28 ET | 500 | 3.7899 |
| 10:30 ET | 300 | 3.765 |
| 10:32 ET | 384 | 3.74 |
| 10:33 ET | 400 | 3.7 |
| 10:35 ET | 100 | 3.72 |
| 10:37 ET | 336 | 3.72 |
| 10:39 ET | 100 | 3.715 |
| 10:42 ET | 610 | 3.74 |
| 10:44 ET | 741 | 3.745 |
| 10:48 ET | 1200 | 3.77 |
| 10:50 ET | 500 | 3.77 |
| 10:51 ET | 400 | 3.84 |
| 10:53 ET | 340 | 3.84 |
| 10:57 ET | 250 | 3.8 |
| 11:00 ET | 1153 | 3.7558 |
| 11:02 ET | 200 | 3.72 |
| 11:04 ET | 300 | 3.715 |
| 11:06 ET | 631 | 3.74 |
| 11:08 ET | 800 | 3.75 |
| 11:09 ET | 100 | 3.75 |
| 11:11 ET | 600 | 3.745 |
| 11:13 ET | 100 | 3.73 |
| 11:15 ET | 100 | 3.75 |
| 11:18 ET | 100 | 3.735 |
| 11:20 ET | 111 | 3.7101 |
| 11:24 ET | 771 | 3.76 |
| 11:29 ET | 100 | 3.76 |
| 11:31 ET | 200 | 3.74 |
| 11:33 ET | 100 | 3.74 |
| 11:38 ET | 300 | 3.7 |
| 11:42 ET | 9992 | 3.745 |
| 11:44 ET | 9979 | 3.7497 |
| 11:45 ET | 100 | 3.73 |
| 11:47 ET | 653 | 3.7298 |
| 11:49 ET | 100 | 3.75 |
| 11:51 ET | 1100 | 3.76 |
| 11:56 ET | 100 | 3.75 |
| 11:58 ET | 200 | 3.75 |
| 12:02 ET | 700 | 3.7143 |
| 12:03 ET | 322 | 3.695 |
| 12:05 ET | 400 | 3.71 |
| 12:07 ET | 425 | 3.7499 |
| 12:09 ET | 100 | 3.75 |
| 12:12 ET | 11428 | 3.7978 |
| 12:14 ET | 10800 | 3.84 |
| 12:16 ET | 200 | 3.85 |
| 12:18 ET | 860 | 3.84 |
| 12:20 ET | 200 | 3.86 |
| 12:21 ET | 316 | 3.87 |
| 12:23 ET | 200 | 3.8799 |
| 12:25 ET | 3044 | 3.88 |
| 12:27 ET | 850 | 3.9 |
| 12:30 ET | 100 | 3.91 |
| 12:32 ET | 1300 | 3.88 |
| 12:34 ET | 318 | 3.88 |
| 12:36 ET | 2043 | 3.86 |
Jun 28, 2024
DJ Monte Rosa Therapeutics Price Target Maintained With a $16.00/Share by Piper Sandler, from 1:47PM ET on Friday Jun 28, 2024 by Dow Jones
1:47PM ET on Friday Jun 28, 2024 by Dow Jones
Jun 27, 2024
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160, from 7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
7:00AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 14, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Monte Rosa Therapeutics Inc | 218.4M | -1.5x | --- |
Zura Bio Ltd | 218.4M | -2.1x | --- |
ESSA Pharma Inc | 218.7M | -7.6x | --- |
Gossamer Bio Inc | 217.1M | -0.9x | --- |
Rezolute Inc | 216.3M | -3.7x | --- |
ATAI Life Sciences NV | 217.6M | -5.4x | --- |
Company Information
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Contact Information
- Headquarters
- 321 Harrison Avenue, Suite 900BOSTON, MA, United States 02118
- Phone
- 617-949-2643
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Andrew Schiff
- President, Chief Executive Officer, Director
- Markus Warmuth
- Chief Operating Officer
- Jennifer Champoux
- Chief Scientific Officer
- Sharon Townson
- Chief Medical Officer
- Filip Janku
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $218.4M |
|---|---|
Revenue (TTM) | $1.1M |
Shares Outstanding | 60.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.53 |
Book Value | $3.57 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | 205.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -13,533.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
